Research programme: influenza virus vaccines - Redbiotec

Drug Profile

Research programme: influenza virus vaccines - Redbiotec

Alternative Names: Influenza VLPs - Redbiotec; RBT 101; RBT 102; RBT 103; RBT 104

Latest Information Update: 07 Nov 2013

Price : $50

At a glance

  • Originator Redbiotec
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 23 Oct 2013 Redbiotec receives grant from EU Edufluvac project for Influenza virus vaccine development in Europe
  • 13 Jan 2012 Preclinical development is ongoing in Switzerland
  • 15 Oct 2009 Preclinical trials in Influenza virus infections in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top